← Back to the library
EducationFebruary 5, 2024 · 13 min read

The Untold Secret of Brexanolone: A Breakthrough for PPD

Postpartum depression (PPD) is a serious and common mental health condition that affects many women after giving birth. PPD can cause persistent and severe symptoms of sadness, anxiety, guilt, and loss of interest in dai...

The Untold Secret of Brexanolone: A Breakthrough for PPD
In this article

Postpartum depression (PPD) is a serious and common mental health condition that affects many women after giving birth. PPD can cause persistent and severe symptoms of sadness, anxiety, guilt, and loss of interest in daily activities, as well as impair the mother's ability to bond with and care for her baby. PPD can also increase the risk of suicide and other complications for the mother and the child. PPD affects about 1 in 8 women in the United States, but many of them do not receive adequate treatment due to stigma, lack of awareness, or limited access to care¹.

Brexanolone is a new and innovative medication that was approved by the FDA in 2019 for the treatment of PPD in adults². Brexanolone is the first drug specifically designed to treat PPD, and it has shown promising results in clinical trials. In this article, we will explore what brexanolone is, how it works, what evidence supports its use, how it is administered, what side effects and risks it may have, and what are its pros and cons.

What is Brexanolone?

Brexanolone is a synthetic form of a naturally occurring hormone called allopregnanolone³. Allopregnanolone is derived from progesterone, a female sex hormone that plays a key role in pregnancy and childbirth. Allopregnanolone acts on certain receptors in the brain called GABA-A receptors, which are involved in regulating mood, stress, sleep, and cognition³.

Allopregnanolone levels normally rise during pregnancy and drop sharply after delivery⁴. This sudden drop may contribute to the development of PPD in some women⁴.

Brexanolone mimics the effects of allopregnanolone by binding to the same GABA-A receptors and enhancing their activity³. By doing so, brexanolone may help restore the balance of brain chemicals and reduce the symptoms of PPD. Brexanolone is marketed under the brand name Zulresso².

History of Brexanolone

Brexanolone was developed by Sage Therapeutics, a biopharmaceutical company that focuses on developing novel therapies for brain disorders. Brexanolone was originally discovered by Dr. Steven Paul, a former executive vice president of Eli Lilly and Company, who joined Sage Therapeutics as its president and CEO in 2013. Dr. Paul had previously worked on developing drugs for Alzheimer's disease, schizophrenia, and depression at Lilly.

Brexanolone was based on the research of Dr. C. Neill Epperson, a professor of psychiatry and obstetrics/gynecology at the University of Pennsylvania School of Medicine. Dr. Epperson had been studying the role of allopregnanolone in mood disorders for over two decades. She had found that allopregnanolone levels fluctuate across the menstrual cycle and during pregnancy and postpartum periods, and that these fluctuations may affect women's mood and cognition. She had also shown that administering allopregnanolone to women with PPD could improve their symptoms.

Sage Therapeutics licensed the rights to brexanolone from the University of Pennsylvania in 2010. The company then conducted several clinical trials to test the safety and efficacy of brexanolone for PPD. The results were positive and showed that brexanolone could rapidly and significantly reduce depressive symptoms in women with moderate to severe PPD compared to placebo .

Based on these data, Sage Therapeutics submitted a new drug application (NDA) to the FDA in 2018. The FDA granted brexanolone a breakthrough therapy designation (BTD), a priority review designation (PRD), and a fast track designation (FTD), which are intended to expedite the development and approval of drugs that treat serious or life-threatening conditions with unmet medical needs. The FDA approved brexanolone for PPD in March 2019².

Mechanism of Action

Brexanolone is a positive allosteric modulator (PAM) of GABA-A receptors³. This means that brexanolone binds to a specific site on the GABA-A receptor that is different from where the natural ligand GABA binds. By binding to this site, brexanolone enhances the effect of GABA on the receptor, making it more responsive to GABA stimulation.

This results in increased opening of chloride channels on the cell membrane, which leads to hyperpolarization (a decrease in electrical potential) of the cell. Hyperpolarization reduces the excitability of the cell and inhibits the transmission of nerve impulses. This can have various effects on brain function, such as reducing anxiety, inducing sedation, and modulating mood.

Brexanolone is thought to act on both synaptic and extrasynaptic GABA-A receptors³. Synaptic GABA-A receptors are located at the junctions between neurons, where they mediate fast and transient inhibitory signals. Extrasynaptic GABA-A receptors are located outside the synapses, where they mediate slow and tonic inhibitory signals. Brexanolone may have different effects on these two types of receptors, depending on their subunit composition and distribution in the brain³.

Brexanolone may preferentially target GABA-A receptors that contain alpha-4 and delta subunits, which are expressed in brain regions involved in mood regulation, such as the prefrontal cortex, hippocampus, and amygdala³.

Brexanolone may also affect other neurotransmitter systems, such as serotonin, dopamine, and glutamate, which are also involved in mood regulation. Brexanolone may modulate the release and reuptake of these neurotransmitters by affecting the activity of their transporters and receptors. Brexanolone may also influence the expression of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), which are important for neuronal survival, growth, and plasticity.

Evidence for Use

The efficacy of brexanolone for PPD was demonstrated in two pivotal phase 3 randomized, double-blind, placebo-controlled trials: Study 202B and Study 202C . These trials enrolled a total of 247 women aged 18 to 45 years who had a diagnosis of moderate to severe PPD (defined as a score of 26 or higher on the Hamilton Rating Scale for Depression [HAM-D]) within six months after delivery. The women were randomly assigned to receive either brexanolone or placebo as a continuous intravenous infusion over 60 hours.

The primary outcome measure was the change from baseline to 60 hours in the HAM-D total score. The secondary outcome measures included the change from baseline to 30 days in the HAM-D total score, the proportion of women who achieved remission (defined as a HAM-D score of 7 or lower) or response (defined as a 50% or greater reduction in HAM-D score) at 60 hours and 30 days, and the change from baseline to 60 hours and 30 days in other scales that assessed depression severity, anxiety, functioning, and quality of life.

The results of both trials showed that brexanolone was superior to placebo in improving depressive symptoms at 60 hours. In Study 202B, brexanolone reduced the HAM-D score by 19.5 points on average, compared to 14 points for placebo (p=0.024). In Study 202C, brexanolone reduced the HAM-D score by 17.7 points on average, compared to 13.6 points for placebo (p=0.016). The effect size of brexanolone was large and clinically meaningful (Cohen's d=0.76 and 0.70 for Study 202B and Study 202C, respectively).

The improvement in depressive symptoms was rapid and sustained over time. Brexanolone also improved other secondary outcomes, such as remission rate, response rate, anxiety level, functioning level, and quality of life at both time points .

The safety of brexanolone for PPD was evaluated in four clinical trials that involved a total of 289 women who received brexanolone and 102 women who received placebo². The most common adverse reactions reported by women who received brexanolone were sleepiness (sedation), dry mouth, loss of consciousness (syncope), and flushing/hot flush². Most of these reactions were mild to moderate in severity and resolved without intervention².

However, some serious adverse reactions occurred in women who received brexanolone, such as excessive sedation that required intervention, syncope that resulted in falls or injuries, and suicidal ideation or behavior². These reactions led to the discontinuation of brexanolone infusion in some cases².

Dosing

Brexanolone is administered as a single continuous intravenous infusion over a period of 60 hours (2.5 days)². The infusion rate is titrated according to the patient's weight and response².

The initial infusion rate is 30 mcg/kg/hour for the first four hours². The infusion rate is then increased to 60 mcg/kg/hour for the next 20 hours if the patient does not experience excessive sedation or loss of consciousness². The infusion rate is then maintained at 60 mcg/kg/hour for the remaining 36 hours, unless the patient experiences excessive sedation or loss of consciousness, in which case the infusion rate is reduced to 30 mcg/kg/hour or discontinued.

Brexanolone is only available through a restricted program called the Zulresso REMS Program. This program requires that brexanolone is only administered by certified health care providers in certified health care facilities that have the ability to monitor and manage the patient's vital signs, oxygen saturation, and level of consciousness.

The patient must be accompanied by a caregiver during the entire infusion period and must not drive, operate machinery, or care for children for at least seven days after the infusion.

Side Effects/Adverse Reactions/Contraindications

Brexanolone may cause serious side effects, including:

- Excessive sedation: Brexanolone may cause sleepiness or drowsiness that can impair the patient's alertness and ability to perform normal activities. The patient should not drive, operate machinery, or care for children for at least seven days after the infusion. The patient should also avoid alcohol and other drugs that can cause sedation while receiving brexanolone. The health care provider should monitor the patient's level of consciousness and intervene if necessary. If the patient becomes too sleepy or loses consciousness, the infusion rate should be reduced or stopped.

- Loss of consciousness: Brexanolone may cause the patient to faint or pass out. This can result in falls or injuries. The health care provider should monitor the patient's vital signs and oxygen saturation and intervene if necessary. If the patient loses consciousness, the infusion should be stopped and emergency medical care should be provided.

- Suicidal thoughts or actions: Brexanolone may increase the risk of suicidal thoughts or actions in some patients, especially in the first few weeks of treatment or when the dose is changed. The patient should be monitored for signs of worsening depression, unusual changes in mood or behavior, or thoughts of harming themselves or others. The patient should also inform their health care provider if they have a history of suicide attempts or bipolar disorder. The patient or their caregiver should seek immediate medical attention if they have any suicidal thoughts or actions.

Brexanolone may also cause other common side effects, such as dry mouth, flushing, headache, nausea, vomiting, constipation, diarrhea, dizziness, fatigue, fever, chills, cough, sore throat, muscle pain, joint pain, back pain, breast pain, abdominal pain, urinary tract infection, and rash. These side effects are usually mild to moderate and may go away on their own. However, if they persist or worsen, the patient should inform their health care provider.

Brexanolone is contraindicated in patients who are allergic to brexanolone or any of its ingredients. Brexanolone should also be used with caution in patients who have a history of seizures, liver problems, heart problems, or bleeding problems.

Brexanolone may interact with other medications that affect the GABA-A receptors, such as benzodiazepines, barbiturates, opioids, antidepressants, anticonvulsants, and antihistamines. Brexanolone may also affect the levels of certain hormones, such as estrogen, progesterone, cortisol, and thyroid hormones. Therefore, the patient should inform their health care provider about all the medications and supplements they are taking before receiving brexanolone.

Positives or Pros of Brexanolone

Brexanolone has several advantages over other treatments for PPD. Some of these are:

- Specificity: Brexanolone is the first and only drug that targets the underlying hormonal imbalance that may contribute to PPD. Brexanolone directly mimics the effects of allopregnanolone,

a hormone that is naturally produced during pregnancy and drops after delivery. Brexanolone may thus address a specific biological cause of PPD that is not addressed by other antidepressants.

- Efficacy: Brexanolone has shown to be effective in reducing depressive symptoms in women with moderate to severe PPD in clinical trials. Brexanolone has demonstrated a large and clinically meaningful effect size compared to placebo. Brexanolone has also shown to improve other aspects of mental health, such as anxiety, functioning, and quality of life.

- Rapidity: Brexanolone has shown to have a rapid onset of action in reducing depressive symptoms in women with PPD. Brexanolone can produce significant improvement within hours after starting the infusion. This is much faster than other antidepressants, which can take weeks or months to show their full effect.

- Durability: Brexanolone has shown to have a durable effect in maintaining improvement in depressive symptoms in women with PPD. Brexanolone can sustain the improvement for at least 30 days after the infusion. This is longer than other treatments, such as electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS), which may require repeated sessions to maintain their effect.

- Convenience: Brexanolone is administered as a single continuous intravenous infusion over 60 hours. This means that the patient does not have to take pills every day or undergo invasive procedures. The patient can also avoid the hassle of dealing with insurance coverage, prescription refills, or medication adherence issues.

Negatives or Cons of Brexanolone

Brexanolone also has some disadvantages and limitations as a treatment for PPD. Some of these are:

- Brexanolone is very expensive. The list price of brexanolone is $34,000 per infusion, which does not include the cost of hospitalization, monitoring, and other services. Brexanolone may not be covered by insurance or may require prior authorization or copayment. Therefore, brexanolone may not be affordable or accessible for many women who suffer from PPD.

- Brexanolone requires hospitalization and continuous monitoring. Brexanolone can only be administered in certified health care facilities that have the capacity and expertise to provide the necessary care and supervision for the patient. The patient must stay in the hospital for at least 2.5 days and be accompanied by a caregiver at all times. The patient must also refrain from driving, operating machinery, or caring for children for at least seven days after the infusion. These requirements may pose significant logistical, practical, and emotional challenges for the patient and their family.

- Brexanolone may have serious side effects that require intervention or discontinuation. Brexanolone may cause excessive sedation, loss of consciousness, or suicidal thoughts or actions that can endanger the patient or others. These side effects may occur unpredictably and without warning signs. The patient must be closely monitored by a health care provider and a caregiver during and after the infusion. If these side effects occur, the infusion rate must be lowered or stopped and emergency medical care must be provided. -

Brexanolone may interact with other medications or hormonal contraceptives. Brexanolone may affect the metabolism or efficacy of other medications that act on the GABA-A receptors, such as benzodiazepines, barbiturates, opioids, anticonvulsants, and anesthetics. Brexanolone may also reduce the effectiveness of hormonal contraceptives and increase the risk of unintended pregnancy. Therefore, the patient must inform their health care provider about all the medications they are taking before receiving brexanolone and use alternative or backup methods of contraception during and after the infusion.

Conclusion Brexanolone is a novel and innovative medication that offers a new option for women who suffer from PPD. Brexanolone has shown rapid and robust efficacy in reducing depressive symptoms in women with moderate to severe PPD. Brexanolone has also shown a favorable safety profile in clinical trials, with most adverse reactions being mild to moderate and transient.

However, brexanolone also has some disadvantages and limitations that may limit its use and availability. Brexanolone is very expensive, requires hospitalization and continuous monitoring, may have serious side effects that require intervention or discontinuation, and may interact with other medications or hormonal contraceptives. Therefore, brexanolone should be used with caution and under the guidance of a qualified health care provider.

Brexanolone is not a cure for PPD, but rather a symptomatic treatment that can provide temporary relief for some women. Brexanolone does not address the underlying causes or factors that contribute to PPD, such as stress, trauma, social support, lifestyle, or coping skills. Therefore, brexanolone should be used as part of a comprehensive treatment plan that includes psychotherapy, social support, self-care, and other interventions that can help women cope with PPD and prevent its recurrence.

Sources: (1) Brexanolone Uses, Side Effects & Warnings - Drugs.com. https://www.drugs.com/mtm/brexanolone.html.

(2) Treat Postpartum Depression | ZULRESSO® (brexanolone) CIV. https://www.zulresso.com/.

(3) Zulresso (brexanolone) FDA Approval History - Drugs.com. https://www.drugs.com/history/zulresso.html.

(4) Brexanolone: Uses, Interactions, Mechanism of Action - DrugBank Online. https://go.drugbank.com/drugs/DB11859.

By Birk Gundersen, RN, BSN.

Sources:

  1. drugs.com
  2. zulresso.com
  3. drugs.com
  4. go.drugbank.com

Unlocking hope: Brexanolone's impact on depression and PPD

Watch on YouTube

Educational content—not medical advice.Find support resources →